MEGGLE introduces blend prediction tool at DDL Edinburgh 2025

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE will again use the Drug Delivery to the Lungs (DDL) Conference in Edinburgh, Scotland, as a launchpad for innovation – this time a novel mobile app to help researchers predict the ideal lactose blend for DPI applications.

MEGGLE is a long-time participant and sponsor of the annual DDL Conference. This time it will again be an exhibitor from Booth 154 at the Edinburgh International Conference Centre, as well as a Silver Sponsor of the event.

Lactose Blend Prediction

A highlight of the stand will be a working smartphone installation of the Lactose Blend Prediction Tool. This allows DPI formulators to accelerate development with data-driven precision. By simply selecting a fine and coarse lactose fraction and defining target blend composition, the tool instantly predicts blend uniformity and calculates the exact component ratios required.

Results are displayed immediately on screen and can be downloaded  via email. All calculations are saved and can be accessed anytime from the login account.

Poster support

MEGGLE is also supporting two of the Poster Presentations, in association with partners.

From Kiel University, MEGGLE-sponsored PhD student Zeredescht Majid will present ‘Magnesium stearate as a force control agent in DPI – revisiting the mechanism of action’. This draws on his work in the research group of Prof. Dr. Regina Scherließ at Kiel, focusing on particle adhesion in powders for inhalation as a collaboration with MEGGLE.

MEGGLE has also partnered with the H&T Presspart specialist Inhalation Technology Product Centre (IPTC) laboratory, whose Director Ameet Sule will post his ‘Evaluation of the effect of fines in Powder blends in combination with a novel capsule-based DPI device’. Ameet’s findings are drawn from blending and characterization analytical testing work carried out in collaboration with MEGGLE and using its lactose grades.

Expert team

The MEGGLE team at DDL 2025 will include Head of Research & Development, Dr.  Ricarda Leister, and Business Development Manager for Inhalation Excipients, Tristan Mul.

Dr. Leister commented:  “We are pleased to be returning to this increasingly valuable conference, which provides up with an ideal platform to share our expertise in lactose-based excipients for DPI applications and to meet our peers and partners.”

About MEGGLE

Bavarian-based MEGGLE is one of the world’s foremost experts in co-processing and powder technology. From its roots as a dairy operation in the late 1880’s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical grade lactose, supplying the pharmaceutical industry with a broad-based and unique lactose product portfolio.

MEGGLE’s Business Unit Excipients has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based pharma excipient solutions, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovation in industrial milk and whey processing. The company constantly strives to develop high-technological, functional products for solid dosage forms and DPI applications, where they can deliver maximum performance.

The company has introduced several revolutionary products, notably Tablettose^®, the world’s first agglomerated pharmaceutical lactose grade for direct tableting, Cellactose^® 80, a pioneering co-processed excipient based on powdered cellulose and lactose for outstanding compression and flow properties and the recently introduced MicroeLac® Plus, a co-processed excipient optimized for exceptional tabletability under direct compression (DC) and continuous direct compression (CDC).

To learn more, visit: https://www.meggle-excipients.com/en/home.html

About DDL 2025

The annual Drug Delivery to the Lungs (DDL) Conference (DDL) has become one of the leading international Pulmonary and Nasal Drug Delivery Conferences, providing an expert forum for scientists, academics, clinicians, regulatory and industry specialists involved in developing medicines for inhalation.

The 36th anniversary meeting, DDL 2025, is a three-day event opening 10 December 2025, again at the Edinburgh International Conference Center at The Exchange, close to University of Edinburgh.

The 2025 conference will feature four themed sessions, including The Pat Burnell Young Investigator Award in which finalist researchers present their work and are judged by the DDL Organizing Committee.

The event is organized by The Aerosol Society, with more information at: https://ddl-conference.com/

Resources

Click on MEGGLE Blend Prediction Tool to learn more.
Click on InhaLac Technical Brochure to download pdf brochure.